1. Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches.
- Author
-
Peciña M, Karp JF, Mathew S, Todtenkopf MS, Ehrich EW, and Zubieta JK
- Subjects
- Analgesics, Opioid pharmacology, Analgesics, Opioid therapeutic use, Depression metabolism, Depressive Disorder, Major drug therapy, Depressive Disorder, Major physiopathology, Drug Overdose, Humans, Mood Disorders drug therapy, Opioid-Related Disorders, Prescription Drugs, United States, Analgesics, Opioid metabolism, Depression drug therapy, Depression physiopathology
- Abstract
The United States is in the midst of an opioid addiction and overdose crisis precipitated and exacerbated by use of prescription opioid medicines. The majority of opioid prescriptions are dispensed to patients with comorbid mood disorders including major depressive disorder (MDD). A growing body of research indicates that the endogenous opioid system is directly involved in the regulation of mood and is dysregulated in MDD. This involvement of the endogenous opioid system may underlie the disproportionate use of opioids among patients with mood disorders. Emerging approaches to address endogenous opioid dysregulation in MDD may yield novel therapeutics that have a low or absent risk of abuse and addiction relative to µ-opioid agonists. Moreover, agents targeting the endogenous opioid system would be expected to yield clinical benefits qualitatively different from conventional monaminergic antidepressants. The development of safe and effective agents to treat MDD-associated endogenous opioid dysregulation may represent a distinct and currently underappreciated means of addressing treatment resistant depression with the potential to attenuate the on-going opioid crisis.
- Published
- 2019
- Full Text
- View/download PDF